Analysts See $-0.79 EPS for Aimmune Therapeutics, Inc. (AIMT)

August 9, 2018 - By Jack Shaw

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Logo

Analysts expect Aimmune Therapeutics, Inc. (NASDAQ:AIMT) to report $-0.79 EPS on August, 14.They anticipate $0.14 EPS change or 21.54 % from last quarter’s $-0.65 EPS. After having $-0.92 EPS previously, Aimmune Therapeutics, Inc.’s analysts see -14.13 % EPS growth. The stock decreased 0.46% or $0.135 during the last trading session, reaching $29.495. About 77,510 shares traded. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has risen 78.81% since August 9, 2017 and is uptrending. It has outperformed by 66.24% the S&P500.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.71 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

More important recent Aimmune Therapeutics, Inc. (NASDAQ:AIMT) news were published by: which released: “3 Solid Mid-Cap Biotechs To Close Out 2018” on July 22, 2018, also published article titled: “Pre-Market Research Reports on Biotech Stocks — Agenus, Aimmune Therapeutics, Akebia Therapeutics, and Alder …”, published: “Aimmune: Societal Benefits” on July 19, 2018. More interesting news about Aimmune Therapeutics, Inc. (NASDAQ:AIMT) was released by: and their article: “Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference …” with publication date: August 07, 2018.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.